Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biocryst Pharmaceuticals

8.44
+0.12001.44%
Volume:4.97M
Turnover:42.30M
Market Cap:1.76B
PE:-19.63
High:8.62
Open:8.43
Low:8.39
Close:8.32
Loading ...

BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
25 Feb

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

Benzinga
·
25 Feb

BioCryst Pharmaceuticals Shares Drop After Wider-Than-Expected 4Q Loss

Dow Jones
·
24 Feb

BUZZ-U.S. STOCKS ON THE MOVE-BioMarin, Azul, Sun Communities

Reuters
·
24 Feb

BUZZ-BioCryst falls on wider-than-expected quarterly loss

Reuters
·
24 Feb

Stock Track | BioCryst Pharmaceuticals Plummets 7% on Q4 Earnings Miss, Raises 2025 Revenue Outlook

Stock Track
·
24 Feb

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
24 Feb

Stock Track | BioCryst Pharmaceuticals Soars 5.21% in Pre-Market on Strong Full-Year Outlook and Positive Pediatric Trial Results

Stock Track
·
24 Feb

BioCryst Pharmaceuticals Falls 2.3% Premarket After Wider Than Expected Q4 Loss

THOMSON REUTERS
·
24 Feb

BioCryst Says Interim Data Show Orladeyo Reduced Attack Rates in Pediatric Patients With Hereditary Angioedema

MT Newswires Live
·
24 Feb

BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows, Revenue Rises

MT Newswires Live
·
24 Feb

BioCryst: Q4 Earnings Snapshot

Associated Press Finance
·
24 Feb

BioCryst Pharmaceuticals- in Jan Got Notice From Annora Pharma That It Submitted Anda for Approval to Make, Sell Generic Version of Orladeyo in US

THOMSON REUTERS
·
24 Feb

BioCryst Pharmaceuticals- Company Intends to Defend Its Intellectual Property Rights Protecting Orladeyo

THOMSON REUTERS
·
24 Feb

Biocryst Pharmaceuticals Expects To Approach Quarterly Positive EPS And Positive Cash Flow In The Second Half Of 2025, And To Be Profitable On An EPS Basis, With Positive Cash Flow, For Full Year 2026

Benzinga
·
24 Feb

GUIDANCE: (BCRX) BioCryst Pharmaceuticals Expects 2025 Revenue Range $560M - $575M, vs. FactSet Est of $548.9M

MT Newswires Live
·
24 Feb

BioCryst Pharmaceuticals Expects Full Year 2025 Total Revenue Of $560M-$575M Compared To Prior Guidance Of $540M-$560M And Consensus Of 545.31M, The Company Increased Its 2025 Outlook For Global Net Orladeyo Revenue To Between $535M-$550M, Previously $515M-$535M

Benzinga
·
24 Feb

BioCryst Pharma Q4 2024 Adj EPS $(0.13) Misses $(0.06) Estimate, Sales $131.53M Beat $130.15M Estimate

Benzinga
·
24 Feb

BRIEF-BioCryst Pharmaceuticals Q4 EPS USD -0.13 Vs. IBES Estimate USD -0.06

Reuters
·
24 Feb

BioCryst Pharmaceuticals Q4 Net Income USD -26.795 Million VS. Ibes Estimate USD -13.2 Million

THOMSON REUTERS
·
24 Feb